title: [Subtypes of mild cognitive impairment in Parkinson's disease and factors predicting its becoming dementia].
abstract: BACKGROUND
  Cognitive impairment may appear at the earliest stages in Parkinson's disease (PD). To assess the prevalence of mild cognitive impairment (MCI) and its different subtypes, as transitional stage, is complicated by the lack of consensus diagnostic criteria.
  
  
  OBJECTIVE
  To review MCI in PD (MCI-PD), diagnostic criteria and predictive factors of conversion to dementia.
  
  
  METHODS
  Systematic review of articles published in Medline (PubMed) using the combination of keywords 'mild cognitive impairment' and 'Parkinson's disease'.
  
  
  RESULTS
  MCI-PD diagnostic criteria published by the Movement Disorders Society are an interesting tool for the diagnosis, in spite they are not validated. Its implementation has the following limitations: 1) the heterogeneity of cognitive deficits described in PD; 2) a variable evolution of cognitive symptoms in PD which difficult the identification of dementia predictors; 3) selection of the more appropriate neuropsychological tests and cut-off points; 4) patient characteristics, disease stage and type of antiparkinsonian treatment.
  
  
  CONCLUSIONS
  Neuropsychological subtypes, neuroimaging, biomarkers or limitation in some instrumental activities seem to be very sensitive for detecting patients with MCI-PD and increased risk of conversion to dementia.
authors.affiliation: Hospital de Henares, Coslada, Espana.
authors.forename: M Elena
authors.initials: ME
authors.lastname: Toribio-Diaz
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Carod-Artal
mesh_terms: D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid; D001284:Atrophy; D001288:Attention; D015415:Biomarkers / Q000134:cerebrospinal fluid; D001921:Brain / Q000473:pathology; D060825:Cognitive Dysfunction / Q000134:cerebrospinal fluid / Q000145:classification* / Q000175:diagnosis / Q000209:etiology; D003430:Cross-Sectional Studies; D003704:Dementia / Q000134:cerebrospinal fluid / Q000453:epidemiology / Q000209:etiology*; D018450:Disease Progression; D056344:Executive Function; D006801:Humans; D007806:Language Disorders / Q000453:epidemiology / Q000209:etiology; D008137:Longitudinal Studies; D008569:Memory Disorders / Q000453:epidemiology / Q000209:etiology; D059906:Neuroimaging; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000453:epidemiology / Q000523:psychology*; D010446:Peptide Fragments / Q000134:cerebrospinal fluid; D015995:Prevalence; D011788:Quality of Life; D012107:Research Design; D012307:Risk Factors; D012720:Severity of Illness Index; D063189:Symptom Assessment; D051844:alpha-Synuclein / Q000134:cerebrospinal fluid
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; D051844:alpha-Synuclein; C075222:amyloid beta-protein (1-42)